Skip to main content

Roche authorized to distribute coronavirus antibody tests

| News

Roche authorized to distribute coronavirus antibody tests


Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.

Roche in Basel (img: Roche)

The US Food and Drug Administration (FDA) has approved Emergency Use Authorization for market launch of the coronavirus antibody test developed by Roche. As of Monday, this will be distributed to labs and hospitals around the world, as detailed in a press release.

“Our best scientists have worked 24/7 over the last few weeks and months to develop a highly reliable antibody test to help fight this pandemic”, comments Thomas Schinecker, CEO of Roche Diagnostics, in the press release. According to information presented by Roche in the press release, the test boasts a specificity score of 99.8% and 100% sensitivity.

Severin Schwan, CEO of the Roche Group, was also quoted in the press release, stating: “I am in particular pleased about the high specificity and sensitivity of our test, which is crucial to support health care systems around the world with a reliable tool to better manage the COVID-19 health crisis”.

Roche has already started to distribute the tests to labs and hospitals around the world. Thanks to extensive, global production capacities, Roche will be in a position to supply the tests in high double-digit million quantities from May onwards, while capacities are also to be gradually expanded as well.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.